

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Confirmatory Assignment
CONVEYING PARTY DATA	
Name	Execution Date
Actimis Pharmaceuticals Inc.	05/11/2009
RECEIVING PARTY DATA	
Name:	Axikin Pharmaceuticals, Inc.
Street Address:	10835 Road to the Cure, Suite 200
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12763072
CORRESPONDENCE DATA	
Fax Number:	(858)314-1150
Phone:	858-314-1200
Email:	cquatrino@jonesday.com, MVDiaz@jonesday.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Jones Day
Address Line 1:	222 East 41st Street
Address Line 4:	New York, NEW YORK 10017-6702
ATTORNEY DOCKET NUMBER:	12702-049-999/191354-049
NAME OF SUBMITTER:	Christina Quatrino
Total Attachments: 11 source=12702-049-999_ConfAssign#page1.tif source=12702-049-999_ConfAssign#page2.tif source=12702-049-999_ConfAssign#page3.tif source=12702-049-999_ConfAssign#page4.tif	

CH \$40.00 12763072

source=12702-049-999_ConfAssign#page5.tif
source=12702-049-999_ConfAssign#page6.tif
source=12702-049-999_ConfAssign#page7.tif
source=12702-049-999_ConfAssign#page8.tif
source=12702-049-999_ConfAssign#page9.tif
source=12702-049-999_ConfAssign#page10.tif
source=12702-049-999_ConfAssign#page11.tif

CONFIRMATORY ASSIGNMENT

WHEREAS, Actimis Pharmaceuticals, Inc., ASSIGNOR, having an office for the transaction of business at 10835 Road to the Cure, Suite 200, San Diego, CA, 92121, was the owner of the inventions disclosed in the Patents and Patent Applications listed in the attached Table 1,

and WHEREAS, Axikin Pharmaceuticals, Inc., ASSIGNEE, having an office for the transaction of business at 10835 Road to the Cure, Suite 200, San Diego, CA, 92121, has obtained the entire right, title and interest in, to and under said Patents and Patent Applications:

ASSIGNOR confirms that, by an Assignment Agreement between said ASSIGNOR and said ASSIGNEE effective June 6, 2008 ("the Assignment Agreement"), for good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, ASSIGNOR's entire right, title and interest in, to and under the said Patents and Patent Applications, and all divisions, renewals and continuations thereof, and all patents which may be granted thereon and all reissues and extensions thereof, and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said Patents and Patent Applications under the Patent Laws of the United States, the International Convention for the Protection of Intellectual Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said inventions in any country or countries foreign to the United States and all extensions, renewals and reissues thereof;

AND ASSIGNOR HEREBY authorizes and requests the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of the Assignment Agreement;

AND ASSIGNOR HEREBY covenants and agrees that ASSIGNOR has full right to convey the entire interest assigned in the Assignment Agreement, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict therewith;

AND ASSIGNOR HEREBY further covenants and agrees that ASSIGNOR will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting said Patents and Patent Applications, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said inventions in all countries.

ACTIMIS PHARMACEUTICALS, INC.

Date May 11, 2009

Peter McWilliams
Name: PETER MCWILLIAMS
Title: CHAIRMAN

State of California)

County of San Mateo)
San Diego

On May 11, 2009, before me, Fortuna B. Miraflores Notary Public, personally appeared Peter McWilliams who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.




TABLE 1

CCR3 — Series One

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-228003 (11582-003-228)	RCK014	PCT	PCT/EP02/09873 WO03/022277	9/4/02 3/20/03	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-036003 (11582-003-036)	RCK014	AR	P0-20103259	8/29/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-059003 (11582-003-059)	RCK014	BS	1467	8/15/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-001003 (11582-003-001)	RCK014	CA	2459432	9/4/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-010003 (11582-003-010)	RCK014	CL	2075-2002	9/6/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-075003 (11582-003-075)	RCK014	DO	P2002/04/09/02	9/4/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-087003 (11582-003-087)	RCK014	GT	PI-2002-0178	9/5/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-091003 (11582-003-091)	RCK014	HN	2002-247	9/6/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-094003 (11582-003-094)	RCK014	JM	18/01/4200	8/30/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-012021 (11582-021-012)	RCK014	JP	2001-272327 2003081937	9/7/01 3/19/03	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-012003 (11582-003-012)	RCK014	JP	2003-526406	9/4/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-241003 (11582-003-241)	RCK014	MY	P1-20023349	9/6/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-011003 (11582-003-011)	RCK014	PE	882-2002 4652	9/6/02 2/16/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-178003 (11582-003-178)	RCK014	PK	771-2002	9/5/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-122003 (11582-003-122)	RCK014	SV	1225-2002	9/6/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-131003 (11582-003-131)	RCK014	TH	75929	8/19/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-185003 (11582-003-185)	RCK014	TW	91-120389 1262187	9/5/02 9/21/06	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders

TABLE 1

CCR3 — Series One

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-999003 (11582-003-999)	RCK014	US	10/489,029 US 2005-0070582	10/21/04 3/31/05	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-040003 (11582-003-040)	RCK014	UY	27430	9/9/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-025003 (11582-003-025)	RCK014	VE	2002-001711	9/6/02	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-227003 (11582-003-227)	RCK014	EP	02772265.1 1461038	9/4/02 8/1/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-002003 (11582-003-002)	RCK014	GB	02772265.1 1461038	9/4/02 8/1/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-003003 (11582-003-003)	RCK014	DE	02772265.1 60221569.2	9/4/02 8/1/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-004003 (11582-003-004)	RCK014	FR	02772265.1 1461038	9/4/02 8/1/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-005003 (11582-003-005)	RCK014	IT	02772265.1 1461038	9/4/02 8/1/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-054003 (11582-003-054)	RCK014	ES	02772265.1 1461038	9/4/02 8/1/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders
129955-227032 (11582-032-227)	RCK014	EP	07013793.0	07/13/07	Arylsulfonamide Derivatives for Use as CCR3 Antagonists in the Treatment of Inflammatory and Immunological Disorders

TABLE I
CCR3 — Series Two

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-228004 (11582-004-228)	RCK 050	PCT	PCT/EP04/002496 WO04/081898	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-999004 (11582-004-999)	RCK 050	US	10/550,482 US2007/0155725 A1	3/11/04 7/5/07	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-036004 (11582-004-036)	RCK 050	AR	PO-40100901	3/18/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-007004 (11582-004-007)	RCK 050	AU	2004-224807	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-037004 (11582-004-037)	RCK 050	BR	PI-0408682-1	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-010004 (11582-004-010)	RCK 050	CL	626-2004	3/24/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-146004 (11582-004-146)	RCK 050	CN	200480013583.5	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-075004 (11582-004-075)	RCK 050	DO	P-2004/05/03/03	3/5/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-087004 (11582-004-087)	RCK 050	GT	PI-2004/0049	3/22/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-056004 (11582-004-056)	RCK 050	IN	2728/CHENP/2005	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-076004 (11582-004-076)	RCK 050	ID	W-00200502579	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-055004 (11582-004-055)	RCK 050	SG	200506132-0	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders

TABLE 1
CCR3 — Series Two

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-122004 (11582-004-122)	RCK 050	SV	2460-2004	3/22/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-091004 (11582-004-091)	RCK 050	HN	2004-103	3/24/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-158004 (11582-004-158)	RCK 050	IL	171069	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-241004 (11582-004-241)	RCK 050	MY	P1-20041019	3/22/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-011004 (11582-004-011)	RCK 050	PE	301-2004	3/23/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-059004 (11582-004-059)	RCK 050	BS	1721	7/26/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-023004 (11582-004-023)	RCK 050	HK	07100055.5 1093317A	1/3/07 3/2/07	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-094004 (11582-004-094)	RCK 050	JM	18/1/4310	7/26/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-012004 (11582-004-012)	RCK 050	JP	2006-504635	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-187004 (11582-004-187)	RCK 050	KR	10-2005-7017943	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-009004 (11582-004-009)	RCK 050	MX	PA/a/2005/010055	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-015004 (11582-004-015)	RCK 050	NO	20054878	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders

TABLE 1
CCR3 — Series Two

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-008004 (11582-004-008)	RCK 050	NZ	542920	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-117004 (11582-004-117)	RCK 050	PH	1-2005-501716	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-178004 (11582-004-178)	RCK 050	PK	103-2004	2/14/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-178021 (11582-024-178)	RCK 050	PK	1152/2006	09/09/06	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-019004 (11582-004-019)	RCK 050	RU	2005132616	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-131004 (11582-004-131)	RCK 050	TH	89083	2/27/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-185004 (11582-004-185)	RCK 050	TW	93-107694	3/23/2004	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-025004 (11582-004-025)	RCK 050	VE	2004-001368	3/24/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-040004 (11582-004-040)	RCK 050	UY	28239	3/23/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-147004 (11582-004-147)	RCK 050	ZA	2005/07806	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-227004 (11582-004-227)	RCK 050	EP	03006293.9	3/24/03	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders
129955-227021 (11582-024-227)	RCK 050	EP	04719389.1 EP 1608374	3/11/04	2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Asthma and Other Inflammatory or Immunological Disorders

TABLE 1
P2Y1 — Target Case

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-228007 (11582-007-228)	LIO131	PCT	PCT/EP01/09243 WO02/14511	8/10/01 2/21/02	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-888007 (11582-007-888)	LIO131	US Prov.	60/224989	8/14/00	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-007007 (11582-007-007)	LIO131	AU	200195454 200195454	10/8/01 2/25/02	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-012007 (11582-007-012)	LIO131	JP	2001-519638	8/10/01	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-227007 (11582-007-227)	LIO131	EP	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-002007 (11582-007-002)	LIO131	GB	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-003007 (11582-007-003)	LIO131	DE	01976066.9 60116515.2-08	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-004007 (11582-007-004)	LIO131	FR	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-005007 (11582-007-005)	LIO131	IT	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-006007 (11582-007-006)	LIO131	BE	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-013007 (11582-007-013)	LIO131	CH	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-016007 (11582-007-016)	LIO131	SE	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-017007 (11582-007-017)	LIO131	DK	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-045007 (11582-007-045)	LIO131	FI	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-014007 (11582-007-014)	LIO131	AT	01976066.9 E315089	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-046007 (11582-007-046)	LIO131	TR	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor
129955-047007 (11582-007-047)	LIO131	EU	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein-Coupled Receptor

TABLE 1
P2Y1 — Target Case

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-048007 (11582-007-048)	LJO131	NL	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-054007 (11582-007-054)	LJO131	ES	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-073007 (11582-007-073)	LJO131	CY	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-085007 (11582-007-085)	LJO131	GR	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-104007 (11582-007-104)	LJO131	MC	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-118007 (11582-007-118)	LJO131	PT	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-155007 (11582-007-155)	LJO131	IE	01976066.9 1311677	8/10/01 1/4/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-999007 (11582-007-999)	LJO131	US	10/344,728 20040038879	8/10/01 2/26/04	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-999022 (11582-022-999)	LJO131	US	11/222,874	9/9/05	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-227022 (11582-023-227)	LJO131	EP	06000083.3	1/3/06	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-023022 (11582-023-023)	LJO131	HK	07100216.1	01/05/07	Regulation of Human P2Y1-Like G Protein- Coupled Receptor
129955-999008 (11582-008-999)	LJO131	US	11/063,894	2/23/05	Regulation of Human P2Y1-Like G Protein- Coupled Receptor

TABLE I
P2Y15 — Series

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-888009 (11582-009-888)	RCK 037	US Prov.	60/413,840	9/27/02	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-888010 (11582-010-888)	RCK 037	US Prov.	60/442,891	1/28/03	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-999010 (11582-010-999)	RCK 037	US	10/529,278	2/2/06	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-007010 (11582-010-007)	RCK 037	AU	2003270265	9/25/03	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-012010 (11582-010-012)	RCK 037	JP	2004-539016	9/25/03	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-001010 (11582-010-001)	RCK 037	CA	2,500,318	9/25/03	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-023010 (11582-010-023)	RCK 037	HK	05112151.3	12/29/05	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-227010 (11582-010-227)	RCK 037	EP	03750626.8	9/25/03	Regulation of Human P2Y15 G Protein-Coupled Receptor
129955-228010 (11582-010-228)	RCK 037	PCT	PCT/EP2003/010666 WO 2004/029626	9/25/03	Regulation of Human P2Y15 G Protein-Coupled Receptor

TABLE I

LIO — 316

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-228013 (11582-013-228)	LIO316	PCT	PCT/EP01/14571 WO02/48358	12/12/01 6/20/02	Regulation of Human Chemokine-Like Receptor
129955-999013 (11582-013-999)	LIO316	US	10/450,590 20040076985	10/27/03 4/22/04	Regulation of Human Chemokine-Like Receptor
129955-007013 (11582-013-007)	LIO316	AU	200228002 200228002	12/12/01 6/24/02	Regulation of Human Chemokine-Like Receptor
129955-012013 (11582-013-012)	LIO316	JP	2002-550075 2004522429	12/12/01 7/29/04	Regulation of Human Chemokine-Like Receptor
129955-227013 (11582-013-227)	LIO316	EP	01989591.1 1343888	12/12/01 9/17/03	Regulation of Human Chemokine-Like Receptor
129955-888011 (11582-013-888)	LIO316	US Prov.	60/255,150	12/14/00	Regulation of Human Chemokine-Like Receptor
129955-888012 (11582-013-888)	LIO316	US Prov.	60/280,110	4/2/01	Regulation of Human Chemokine-Like Receptor
129955-888013 (11582-013-888)	LIO316	US Prov.	60/299,474	6/21/01	Regulation of Human Chemokine-Like Receptor

TABLE 1
RC Kinase

Jones Day CAM (Docket)	Client Ref.	Region/ Country Code	Serial No. Patent/Publication	Filed Pub. Date	Title
129955-228016 (11582-016-228)	RCK 56	PCT	PCT/EP2004/0064 74 WO2005/001083	6/16/04 1/6/05	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-227016 (11582-016-227)	RCK 56	EP	03014688.0	6/27/03	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-227015 (11582-015-227)	RCK 56	EP	04004818.3	3/2/04	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-001016 (11582-016-001)	RCK 56	CA	2,530,663	6/16/04	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-007016 (11582-016-007)	RCK 56	AU	2004251181	6/16/04	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-012016 (11582-016-012)	RCK 56	JP	2006-515949	6/16/04	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-227024 (11582-026-227)	RCK 56	EP	04739941.5	6/16/04	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-023024 (11582-026-023)	RCK 56	HK	06111261.3	10/12/06	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)
129955-999016 (11582-016-999)	RCK 56	US	10/561,570	12/20/05	Regulation of Kinase, 'Regulated in COPD Kinase' (RC Kinase)